Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers?

A population-based study

O. M. McNally (Lead / Corresponding author), E. Delaney, R. D. Petty, M. E. Cruickshank, A. W. Hutcheon, D. E. Parkin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

NICE guidance recommends the use of paclitaxel and a platinum therapy for all cases of ovarian cancer. We report our experience of treating 133 patients with ovarian cancer over a 3-year period. Where indicated, 91% received chemotherapy. A taxane/platinum combination was found to be appropriate in 63% of patients only.

Original languageEnglish
Pages (from-to)966-967
Number of pages2
JournalBritish Journal of Cancer
Volume89
Issue number6
DOIs
Publication statusPublished - 15 Sep 2003

Fingerprint

Platinum
Ovarian Neoplasms
Drug Therapy
Paclitaxel
Population
Therapeutics
taxane

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols
  • Carboplatin
  • Combined Modality Therapy
  • Female
  • Humans
  • Middle Aged
  • Mixed Tumor, Mullerian
  • Neoplasm Staging
  • Neoplasms, Glandular and Epithelial
  • Ovarian Neoplasms
  • Paclitaxel
  • Practice Guidelines as Topic
  • Prospective Studies
  • Radiotherapy Dosage
  • Survival Rate
  • Taxoids

Cite this

@article{ea5e15d7619f4d46a0ed35b2a934818a,
title = "Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers?: A population-based study",
abstract = "NICE guidance recommends the use of paclitaxel and a platinum therapy for all cases of ovarian cancer. We report our experience of treating 133 patients with ovarian cancer over a 3-year period. Where indicated, 91{\%} received chemotherapy. A taxane/platinum combination was found to be appropriate in 63{\%} of patients only.",
keywords = "Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Combined Modality Therapy, Female, Humans, Middle Aged, Mixed Tumor, Mullerian, Neoplasm Staging, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Paclitaxel, Practice Guidelines as Topic, Prospective Studies, Radiotherapy Dosage, Survival Rate, Taxoids",
author = "McNally, {O. M.} and E. Delaney and Petty, {R. D.} and Cruickshank, {M. E.} and Hutcheon, {A. W.} and Parkin, {D. E.}",
year = "2003",
month = "9",
day = "15",
doi = "10.1038/sj.bjc.6601071",
language = "English",
volume = "89",
pages = "966--967",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Cancer Research UK",
number = "6",

}

Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study. / McNally, O. M. (Lead / Corresponding author); Delaney, E.; Petty, R. D.; Cruickshank, M. E.; Hutcheon, A. W.; Parkin, D. E.

In: British Journal of Cancer, Vol. 89, No. 6, 15.09.2003, p. 966-967.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers?

T2 - A population-based study

AU - McNally, O. M.

AU - Delaney, E.

AU - Petty, R. D.

AU - Cruickshank, M. E.

AU - Hutcheon, A. W.

AU - Parkin, D. E.

PY - 2003/9/15

Y1 - 2003/9/15

N2 - NICE guidance recommends the use of paclitaxel and a platinum therapy for all cases of ovarian cancer. We report our experience of treating 133 patients with ovarian cancer over a 3-year period. Where indicated, 91% received chemotherapy. A taxane/platinum combination was found to be appropriate in 63% of patients only.

AB - NICE guidance recommends the use of paclitaxel and a platinum therapy for all cases of ovarian cancer. We report our experience of treating 133 patients with ovarian cancer over a 3-year period. Where indicated, 91% received chemotherapy. A taxane/platinum combination was found to be appropriate in 63% of patients only.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carboplatin

KW - Combined Modality Therapy

KW - Female

KW - Humans

KW - Middle Aged

KW - Mixed Tumor, Mullerian

KW - Neoplasm Staging

KW - Neoplasms, Glandular and Epithelial

KW - Ovarian Neoplasms

KW - Paclitaxel

KW - Practice Guidelines as Topic

KW - Prospective Studies

KW - Radiotherapy Dosage

KW - Survival Rate

KW - Taxoids

U2 - 10.1038/sj.bjc.6601071

DO - 10.1038/sj.bjc.6601071

M3 - Article

VL - 89

SP - 966

EP - 967

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -